Project Grant R01CA296867
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $473K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award of $702,748 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research at Weill Medical College of Cornell University to determine the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer therapies. The project aims to characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, with the goal of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The National Cancer Institute awarded a $148,050 Project Grant under the Cancer Research Manpower federal grant program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports research to study the role of the APOBEC3 family of cytosine deaminases in driving genomic instability and mutagenesis in lung cancer. The project aims to identify the specific APOBEC3 enzymes responsible for lung cancer mutagenesis and develop novel tools to measure APOBEC3 activity. This research...
- This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to Harvard T.H. Chan School of Public Health to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer. The research aims to leverage multi-omic data (genetics, genomics, transcriptomics, proteomics) from over 80,000 NSCLC...
- The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon gamma (IFNγ) signaling pathway in the lung tumor microenvironment and its impact on tumor immunity. The project aims to deconvolute how various components of the IFNγ pathway, including the negative regulator SOCS1, influence immune cell infiltration and response to immune...
- The U.S. National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a period of performance from February 1, 2025 to January 31, 2027, will fund research to study the role of aberrant mRNA splicing in cancer cell heterogeneity and its potential as a target for immunotherapeutic strategies. The research aims to utilize advanced computational and single-cell approaches...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- This $204,027 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting the Weill Medical College of Cornell University in expanding single-cell and spatial technologies to link clonal genotypes with phenotypes during cancer evolution. The grant aims to develop advanced single-cell methods that can capture multiple data modalities, including genotypes, transcriptomes, methylomes, and protein expression, to better understand how somatic...